{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,25]],"date-time":"2026-10-25T20:25:05Z","timestamp":1792959905987,"version":"4.5.0"},"reference-count":44,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T00:00:00Z","timestamp":1769212800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T00:00:00Z","timestamp":1771286400000},"content-version":"vor","delay-in-days":24,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005009122"],"award-info":[{"award-number":["005009122"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005009122"],"award-info":[{"award-number":["005009122"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000897","name":"Cystic Fibrosis Foundation","doi-asserted-by":"publisher","award":["005009122"],"award-info":[{"award-number":["005009122"]}],"id":[{"id":"10.13039\/100000897","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Lega Italiana Fibrosi Cistica Sezione Veneto"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Respir Res"],"DOI":"10.1186\/s12931-026-03494-9","type":"journal-article","created":{"date-parts":[[2026,1,24]],"date-time":"2026-01-24T12:04:45Z","timestamp":1769256285000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":3,"title":["Modulation of immune responses by elexacaftor\/tezacaftor\/ivacaftor therapy in cystic fibrosis: data from a compassionate use program"],"prefix":"10.1186","volume":"27","author":[{"given":"Francesca","family":"Lucca","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anna","family":"Pianazzola","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ilaria","family":"Meneghelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppina","family":"Catanzaro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Sabbioni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gloria","family":"Tridello","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anca Manuela","family":"Hristodor","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erik","family":"De Luca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Menichetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Breveglieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Teresa","family":"Altieri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marica","family":"Bordicchia","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Fabrizzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisabetta","family":"Ferretti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Lippi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirco","family":"Ros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monica","family":"Borgatti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marco","family":"Cipolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Valentino","family":"Bezzerri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,1,24]]},"reference":[{"key":"3494_CR1","doi-asserted-by":"publisher","first-page":"15010","DOI":"10.1038\/nrdp.2015.10","volume":"1","author":"F Ratjen","year":"2015","unstructured":"Ratjen F, Bell SC, Rowe SM, Goss CH, Quittner AL, Bush A. Cystic fibrosis. Nat Reviews Disease Primers. 2015;1:15010.","journal-title":"Nat Reviews Disease Primers"},{"key":"3494_CR2","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1007\/s00018-016-2387-7","volume":"74","author":"CM Farinha","year":"2017","unstructured":"Farinha CM, Canato S. From the Endoplasmic reticulum to the plasma membrane: mechanisms of CFTR folding and trafficking. Cell Mol Life Sci. 2017;74:39\u201355.","journal-title":"Cell Mol Life Sci"},{"key":"3494_CR3","doi-asserted-by":"crossref","unstructured":"Montgomery ST, Mall MA, Kicic A, Stick SM. CF A. Hypoxia and sterile inflammation in cystic fibrosis airways: mechanisms and potential therapies. Eur Respir J 2017, 49.","DOI":"10.1183\/13993003.00903-2016"},{"key":"3494_CR4","doi-asserted-by":"publisher","first-page":"134","DOI":"10.1136\/thoraxjnl-2017-210134","volume":"73","author":"RD Gray","year":"2018","unstructured":"Gray RD, Hardisty G, Regan KH, Smith M, Robb CT, Duffin R, Mackellar A, Felton JM, Paemka L, McCullagh BN, et al. Delayed neutrophil apoptosis enhances NET formation in cystic fibrosis. Thorax. 2018;73:134\u201344.","journal-title":"Thorax"},{"key":"3494_CR5","doi-asserted-by":"publisher","first-page":"377","DOI":"10.1183\/09031936.98.11020377","volume":"11","author":"D Worlitzsch","year":"1998","unstructured":"Worlitzsch D, Herberth G, Ulrich M, Doring G. Catalase, myeloperoxidase and hydrogen peroxide in cystic fibrosis. Eur Respir J. 1998;11:377\u201383.","journal-title":"Eur Respir J"},{"key":"3494_CR6","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.freeradbiomed.2020.03.001","volume":"152","author":"N Dickerhof","year":"2020","unstructured":"Dickerhof N, Huang J, Min E, Micha\u00eblsson E, Lindstedt E-L, Pearson JF, Kettle AJ, Day BJ. Myeloperoxidase Inhibition decreases morbidity and oxidative stress in mice with cystic fibrosis-like lung inflammation. Free Radic Biol Med. 2020;152:91\u20139.","journal-title":"Free Radic Biol Med"},{"key":"3494_CR7","doi-asserted-by":"publisher","first-page":"4335","DOI":"10.3390\/jcm14124335","volume":"14","author":"F Lucca","year":"2025","unstructured":"Lucca F, Meneghelli I, Tridello G, Buniotto F, Cucchetto G, Volpi S, Pintani E, Bezzerri V, Cipolli M. Reported adverse events in patients with CF receiving treatment with Elexacaftor\/Tezacaftor\/Ivacaftor: 5 years observational study. J Clin Med. 2025;14:4335.","journal-title":"J Clin Med"},{"key":"3494_CR8","doi-asserted-by":"publisher","first-page":"114176","DOI":"10.1016\/j.jpeds.2024.114176","volume":"274","author":"V Terlizzi","year":"2024","unstructured":"Terlizzi V, Fevola C, Presti S, Castaldo A, Dacc\u00f2 V, Claut L, Sepe A, Majo F, Casciaro R, Esposito I, et al. Reported adverse events in a multicenter cohort of patients ages 6\u201318 years with cystic fibrosis and at least one F508del allele receiving Elexacaftor\/Tezacaftor\/Ivacaftor. J Pediatr. 2024;274:114176.","journal-title":"J Pediatr"},{"key":"3494_CR9","doi-asserted-by":"publisher","first-page":"299","DOI":"10.1164\/rccm.202308-1525OC","volume":"209","author":"B Ramsey","year":"2024","unstructured":"Ramsey B, Correll CU, Demaso DR, McKone E, Tullis E, Taylor-Cousar JL, Chu C, Volkova N, Ahluwalia N, Waltz D, et al. Elexacaftor\/Tezacaftor\/Ivacaftor treatment and Depression-related events. Am J Respir Crit Care Med. 2024;209:299\u2013306.","journal-title":"Am J Respir Crit Care Med"},{"key":"3494_CR10","doi-asserted-by":"publisher","first-page":"e0304555","DOI":"10.1371\/journal.pone.0304555","volume":"19","author":"HH Jarosz-Griffiths","year":"2024","unstructured":"Jarosz-Griffiths HH, Gillgrass L, Caley LR, Spoletini G, Clifton IJ, Etherington C, Savic S, McDermott MF, Peckham D. Anti-inflammatory effects of elexacaftor\/tezacaftor\/ivacaftor in adults with cystic fibrosis heterozygous for F508del. PLoS ONE. 2024;19:e0304555.","journal-title":"PLoS ONE"},{"key":"3494_CR11","doi-asserted-by":"crossref","unstructured":"Garc\u00eda MS, Madrid-Carbajal CJ, Pel\u00e1ez A, Moreno RMG, Alonso EF, Garc\u00eda BP, Punter RMG, Ancochea J, Bachiller JME, Ruiz JDH, Clemente MG. The role of triple CFTR modulator therapy in reducing systemic inflammation in cystic fibrosis. Lung 2025, 203.","DOI":"10.1007\/s00408-025-00806-6"},{"key":"3494_CR12","doi-asserted-by":"crossref","unstructured":"Sagel SD, Poore TS, Wagner BD, Xie J, Heltshe SL, Cross M, Bratcher PE, Taylor-Cousar JL, Wilson A, McBennett K, et al. Long-term reductions in inflammation in people with cystic fibrosis treated with Elexacaftor\/Tezacaftor\/Ivacaftor. Annals Am Thorac Soc; 2025.","DOI":"10.1513\/AnnalsATS.202507-817OC"},{"key":"3494_CR13","doi-asserted-by":"crossref","unstructured":"Pepe A, Fevola C, Dolce D, Campana S, Ravenni N, Taccetti G, Salvatore D, Terlizzi V. Elexacaftor\/tezacaftor\/ivacaftor and inflammation in children and adolescents with cystic fibrosis: a retrospective dual-center cohort study. Ther Adv Respir Dis 2025, 19.","DOI":"10.1177\/17534666251314706"},{"key":"3494_CR14","doi-asserted-by":"publisher","first-page":"2300216","DOI":"10.1183\/13993003.00216-2023","volume":"61","author":"EM Bruscia","year":"2023","unstructured":"Bruscia EM. The effects of elexacaftor\/tezacaftor\/ivacaftor beyond the epithelium: spurring macrophages to fight infections. Eur Respir J. 2023;61:2300216.","journal-title":"Eur Respir J"},{"key":"3494_CR15","doi-asserted-by":"crossref","unstructured":"Ozuna H, Bojja D, Partida-Sanchez S, Hall-Stoodley L, Amer A, Britt RD, Sheikh S, Frank DA, Wang W, Kang B-Y et al. Proteomics profiling of inflammatory responses to elexacaftor\/tezacaftor\/ivacaftor in cystic fibrosis. Front Immunol 2025, 16.","DOI":"10.3389\/fimmu.2025.1486784"},{"key":"3494_CR16","doi-asserted-by":"crossref","unstructured":"Maher RE, Cytlak-Chaudhuri UM, Aleem S, Barry P, Brice DP, Caama\u00f1o Guti\u00e9rrez E, Driver K, Emmott E, Rothwell A, Smith E et al. Effect of elexacaftor\/tezacaftor\/ivacaftor on systemic inflammation in cystic fibrosis. Thorax 2025:thorax\u20132024.","DOI":"10.1101\/2024.07.25.24310916"},{"key":"3494_CR17","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1136\/thorax-2022-219943","volume":"78","author":"M Casey","year":"2023","unstructured":"Casey M, Gabillard-Lefort C, McElvaney OF, McElvaney OJ, Carroll T, Heeney RC, Gunaratnam C, Reeves EP, Murphy MP, McElvaney NG. Effect of elexacaftor\/tezacaftor\/ivacaftor on airway and systemic inflammation in cystic fibrosis. Thorax. 2023;78:835\u20139.","journal-title":"Thorax"},{"key":"3494_CR18","doi-asserted-by":"publisher","first-page":"2202153","DOI":"10.1183\/13993003.02153-2022","volume":"62","author":"L Schaupp","year":"2023","unstructured":"Schaupp L, Addante A, V\u00f6ller M, Fentker K, Kuppe A, Bardua M, Duerr J, Piehler L, R\u00f6hmel J, Thee S, et al. Longitudinal effects of elexacaftor\/tezacaftor\/ivacaftor on sputum viscoelastic properties, airway infection and inflammation in patients with cystic fibrosis. Eur Respir J. 2023;62:2202153.","journal-title":"Eur Respir J"},{"key":"3494_CR19","doi-asserted-by":"publisher","first-page":"1923","DOI":"10.1093\/bioinformatics\/btu115","volume":"30","author":"C Lee","year":"2014","unstructured":"Lee C, Huang C-H. LASAGNA-Search 2.0: integrated transcription factor binding site search and visualization in a browser. Bioinformatics. 2014;30:1923\u20135.","journal-title":"Bioinformatics"},{"key":"3494_CR20","doi-asserted-by":"publisher","first-page":"529","DOI":"10.1164\/rccm.202108-1986OC","volume":"205","author":"DP Nichols","year":"2022","unstructured":"Nichols DP, Paynter AC, Heltshe SL, Donaldson SH, Frederick CA, Freedman SD, Gelfond D, Hoffman LR, Kelly A, Narkewicz MR, et al. Clinical effectiveness of Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis: A clinical trial. Am J Respir Crit Care Med. 2022;205:529\u201339.","journal-title":"Am J Respir Crit Care Med"},{"key":"3494_CR21","doi-asserted-by":"publisher","first-page":"100690","DOI":"10.1016\/j.lanepe.2023.100690","volume":"32","author":"S Sutharsan","year":"2023","unstructured":"Sutharsan S, Dillenhoefer S, Welsner M, Stehling F, Brinkmann F, Burkhart M, Ellemunter H, Dittrich A-M, Smaczny C, Eickmeier O, et al. Impact of elexacaftor\/tezacaftor\/ivacaftor on lung function, nutritional status, pulmonary exacerbation frequency and sweat chloride in people with cystic fibrosis: real-world evidence from the German CF registry. Lancet Reg Health - Europe. 2023;32:100690.","journal-title":"Lancet Reg Health - Europe"},{"key":"3494_CR22","doi-asserted-by":"crossref","unstructured":"Sagel SD, Vu P, Heltshe SL, Solomon GM, Kelly A, Pittman J, Rosenfeld M, Ratjen F. Elexacaftor\/tezacaftor\/ivacaftor is associated with long-term reduction in use of chronic respiratory therapies in cystic fibrosis. J Cyst Fibros 2025.","DOI":"10.1016\/j.jcf.2025.11.016"},{"key":"3494_CR23","doi-asserted-by":"publisher","first-page":"1072","DOI":"10.1016\/j.jcf.2024.04.013","volume":"23","author":"G Alicandro","year":"2024","unstructured":"Alicandro G, Gramegna A, Bellino F, Sciarrabba SC, Lanfranchi C, Contarini M, Retucci M, Dacc\u00f2 V, Blasi F. Heterogeneity in response to Elexacaftor\/Tezacaftor\/Ivacaftor in people with cystic fibrosis. J Cyst Fibros. 2024;23:1072\u20139.","journal-title":"J Cyst Fibros"},{"key":"3494_CR24","doi-asserted-by":"publisher","first-page":"676","DOI":"10.1016\/j.jcf.2024.02.001","volume":"23","author":"ET Zemanick","year":"2024","unstructured":"Zemanick ET, Emerman I, McCreary M, Mayer-Hamblett N, Warden MN, Odem-Davis K, Vandevanter DR, Ren CL, Young J, Konstan MW. Heterogeneity of CFTR modulator-induced sweat chloride concentrations in people with cystic fibrosis. J Cyst Fibros. 2024;23:676\u201384.","journal-title":"J Cyst Fibros"},{"key":"3494_CR25","doi-asserted-by":"publisher","first-page":"825","DOI":"10.1002\/ppul.26261","volume":"58","author":"S Sheikh","year":"2023","unstructured":"Sheikh S, Britt RD, Ryan-Wenger NA, Khan AQ, Lewis BW, Gushue C, Ozuna H, Jaganathan D, McCoy K, Kopp BT. Impact of elexacaftor\u2013tezacaftor\u2013ivacaftor on bacterial colonization and inflammatory responses in cystic fibrosis. Pediatr Pulmonol. 2023;58:825\u201333.","journal-title":"Pediatr Pulmonol"},{"key":"3494_CR26","doi-asserted-by":"crossref","unstructured":"Mehta AM, Lee I, Li G, Jones MK, Hanson L, Lonabaugh K, List R, Borish L, Albon DP. The impact of CFTR modulator triple therapy on type 2 inflammatory response in patients with cystic fibrosis. Allergy Asthma Clin Immunol 2023, 19.","DOI":"10.1186\/s13223-023-00822-2"},{"key":"3494_CR27","doi-asserted-by":"publisher","first-page":"L905","DOI":"10.1152\/ajplung.00272.2024","volume":"327","author":"TH Hampton","year":"2024","unstructured":"Hampton TH, Barnaby R, Roche C, Nymon A, Fukutani KF, Mackenzie TA, Charpentier LA, Stanton BA. Gene expression responses of CF airway epithelial cells exposed to elexacaftor\/tezacaftor\/ivacaftor suggest benefits beyond improved CFTR channel function. Am J Physiology-Lung Cell Mol Physiol. 2024;327:L905\u201316.","journal-title":"Am J Physiology-Lung Cell Mol Physiol"},{"key":"3494_CR28","doi-asserted-by":"publisher","first-page":"157","DOI":"10.1016\/j.jcf.2024.09.005","volume":"24","author":"O Cinek","year":"2025","unstructured":"Cinek O, Furstova E, Novotna S, Hubackova K, Dousova T, Borek-Dohalska L, Drevinek P. Gene expression profile of intestinal organoids from people with cystic fibrosis upon exposure to elexacaftor\/tezacaftor\/ivacaftor. J Cyst Fibros. 2025;24:157\u201363.","journal-title":"J Cyst Fibros"},{"key":"3494_CR29","doi-asserted-by":"publisher","first-page":"226","DOI":"10.1089\/jir.2015.0054","volume":"36","author":"A Rani","year":"2016","unstructured":"Rani A, Murphy JJ. STAT5 in cancer and immunity. J Interferon Cytokine Res. 2016;36:226\u201337.","journal-title":"J Interferon Cytokine Res"},{"key":"3494_CR30","doi-asserted-by":"publisher","first-page":"17089","DOI":"10.1073\/pnas.0508517102","volume":"102","author":"A Kimura","year":"2005","unstructured":"Kimura A, Naka T, Muta T, Takeuchi O, Akira S, Kawase I, Kishimoto T. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK\u2013STAT. Proc Natl Acad Sci. 2005;102:17089\u201394.","journal-title":"Proc Natl Acad Sci"},{"key":"3494_CR31","doi-asserted-by":"crossref","unstructured":"Nagenborg J, Jin H, Ruder AV, Temmerman L, Mees B, Schalkwijk C, M\u00fcller-Klieser D, Berg T, Goossens P, Donners MMPC, Biessen EAL. GM-CSF-activated STAT5A regulates macrophage functions and inflammation in atherosclerosis. Front Immunol 2023, 14.","DOI":"10.3389\/fimmu.2023.1165306"},{"key":"3494_CR32","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1038\/s41435-023-00217-8","volume":"24","author":"I Vanmeerbeek","year":"2023","unstructured":"Vanmeerbeek I, Naulaerts S, Garg AD. Reverse translation: the key to increasing the clinical success of immunotherapy? Genes Immun. 2023;24:217\u20139.","journal-title":"Genes Immun"},{"key":"3494_CR33","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1164\/rccm.202310-1836OC","volume":"209","author":"J Loske","year":"2024","unstructured":"Loske J, V\u00f6ller M, Lukassen S, Stahl M, Th\u00fcrmann L, Seegebarth A, R\u00f6hmel J, Wisniewski S, Messingschlager M, Lorenz S, et al. Pharmacological improvement of cystic fibrosis transmembrane conductance regulator function rescues airway epithelial homeostasis and host defense in children with cystic fibrosis. Am J Respir Crit Care Med. 2024;209:1338\u201350.","journal-title":"Am J Respir Crit Care Med"},{"key":"3494_CR34","doi-asserted-by":"crossref","unstructured":"Westh\u00f6lter D, Raspe J, Uebner H, Pipping J, Schmitz M, Stra\u00dfburg S, Sutharsan S, Welsner M, Taube C, Reuter S. Regulatory T cell enhancement in adults with cystic fibrosis receiving Elexacaftor\/Tezacaftor\/Ivacaftor therapy. Front Immunol 2023, 14.","DOI":"10.3389\/fimmu.2023.1107437"},{"key":"3494_CR35","doi-asserted-by":"publisher","first-page":"2891","DOI":"10.3390\/ijms21082891","volume":"21","author":"P Scott","year":"2020","unstructured":"Scott P, Anderson K, Singhania M, Cormier R. Cystic Fibrosis, CFTR, and colorectal cancer. Int J Mol Sci. 2020;21:2891.","journal-title":"Int J Mol Sci"},{"key":"3494_CR36","doi-asserted-by":"publisher","first-page":"71","DOI":"10.1016\/j.cytogfr.2016.02.010","volume":"29","author":"K Blaszczyk","year":"2016","unstructured":"Blaszczyk K, Nowicka H, Kostyrko K, Antonczyk A, Wesoly J, Bluyssen HAR. The unique role of STAT2 in constitutive and IFN-induced transcription and antiviral responses. Cytokine Growth Factor Rev. 2016;29:71\u201381.","journal-title":"Cytokine Growth Factor Rev"},{"key":"3494_CR37","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1002\/cac2.12274","volume":"42","author":"Z Wang","year":"2022","unstructured":"Wang Z, Chen W, Zuo L, Xu M, Wu Y, Huang J, Zhang X, Li Y, Wang J, Chen J, et al. The Fibrillin-1\/VEGFR2\/STAT2 signaling axis promotes chemoresistance via modulating Glycolysis and angiogenesis in ovarian cancer organoids and cells. Cancer Commun (Lond). 2022;42:245\u201365.","journal-title":"Cancer Commun (Lond)"},{"key":"3494_CR38","doi-asserted-by":"publisher","first-page":"2476","DOI":"10.1016\/j.jid.2022.01.024","volume":"142","author":"D Wang","year":"2022","unstructured":"Wang D, Fu Z, Gao L, Zeng J, Xiang Y, Zhou L, Tong X, Wang XQ, Lu J. Increased IRF9-STAT2 signaling leads to adaptive resistance toward targeted therapy in melanoma by restraining GSDME-Dependent pyroptosis. J Invest Dermatol. 2022;142:2476\u2013e24872479.","journal-title":"J Invest Dermatol"},{"key":"3494_CR39","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1038\/s12276-020-00506-6","volume":"52","author":"CJ Lee","year":"2020","unstructured":"Lee CJ, An HJ, Cho ES, Kang HC, Lee JY, Lee HS, Cho YY. Stat2 stability regulation: an intersection between immunity and carcinogenesis. Exp Mol Med. 2020;52:1526\u201336.","journal-title":"Exp Mol Med"},{"key":"3494_CR40","doi-asserted-by":"crossref","unstructured":"Capraro M, Pedrazzi M, De Tullio R, Manfredi M, Cresta F, Castellani C, Averna M. Modulation of plasmatic matrix metalloprotease 9: A promising new tool for Understanding the variable clinical responses of patients with cystic fibrosis to cystic fibrosis transmembrane conductance regulator modulators. Int J Mol Sci 2023, 24.","DOI":"10.3390\/ijms241713384"},{"key":"3494_CR41","doi-asserted-by":"publisher","first-page":"6069","DOI":"10.4049\/jimmunol.1100821","volume":"187","author":"V Bezzerri","year":"2011","unstructured":"Bezzerri V, Borgatti M, Finotti A, Tamanini A, Gambari R, Cabrini G. Mapping the transcriptional machinery of the IL-8 gene in human bronchial epithelial cells. J Immunol. 2011;187:6069\u201381.","journal-title":"J Immunol"},{"key":"3494_CR42","doi-asserted-by":"crossref","unstructured":"Jin W. Role of JAK\/STAT3 signaling in the regulation of Metastasis, the transition of cancer stem Cells, and chemoresistance of cancer by Epithelial-Mesenchymal transition. Cells 2020, 9.","DOI":"10.3390\/cells9010217"},{"key":"3494_CR43","doi-asserted-by":"publisher","first-page":"920","DOI":"10.1038\/s41419-020-03119-z","volume":"11","author":"MC Quaresma","year":"2020","unstructured":"Quaresma MC, Pankonien I, Clarke LA, Sousa LS, Silva IAL, Railean V, Dou\u0161ov\u00e1 T, Fuxe J, Amaral MD. Mutant CFTR drives TWIST1 mediated epithelial-mesenchymal transition. Cell Death Dis. 2020;11:920.","journal-title":"Cell Death Dis"},{"key":"3494_CR44","doi-asserted-by":"publisher","first-page":"33165","DOI":"10.1038\/srep33165","volume":"6","author":"V Bezzerri","year":"2016","unstructured":"Bezzerri V, Vella A, Calcaterra E, Finotti A, Gasparello J, Gambari R, Assael BM, Cipolli M, Sorio C. New insights into the Shwachman-Diamond Syndrome-related haematological disorder: hyper-activation of mTOR and STAT3 in leukocytes. Sci Rep. 2016;6:33165.","journal-title":"Sci Rep"}],"container-title":["Respiratory Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12931-026-03494-9","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03494-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12931-026-03494-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,17]],"date-time":"2026-02-17T11:54:04Z","timestamp":1771329244000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12931-026-03494-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,24]]},"references-count":44,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["3494"],"URL":"https:\/\/doi.org\/10.1186\/s12931-026-03494-9","relation":{},"ISSN":["1465-993X"],"issn-type":[{"value":"1465-993X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,24]]},"assertion":[{"value":"19 August 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 January 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study has been reviewed and approved by the Ethics Committees of the Azienda Ospedaliera Universitaria Integrata, Verona (approval no. 216CET) and Sapienza University of Rome (territorial Lazio CE approval N.5943). All participating patients and subjects provided signed informed consent before enrollment according to the regulations of the Ethics Committees.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"81"}}